Cyramza®

Active substance

ramucirumab

Holder

S.A. Eli Lilly N.V. Belgium

Status

Closed

Indication

treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with systemic therapy

Public documents

Approbation

Information for the patient

Informed consent

Last update

19/04/2021

Last updated on 13/02/2024